AstraZeneca Acquires Omniose, Adding Bioconjugate Vaccine Platform

AstraZeneca has acquired Omniose, a preclinical biotechnology company, adding a bioconjugation platform for conjugate vaccines to its infectious disease portfolio, Omniose announced Nov. 10.¹ Omniose becomes a wholly owned subsidiary and part of AstraZeneca’s Infectious Disease Unit, following a three-year exclusive research collaboration between the two.¹

The transaction puts a manufacturing question at the center of vaccine strategy: whether assembling an antigen and its carrier protein inside one engineered cell can simplify a process that has traditionally relied on multiple chemical steps.

Benjamin Moutier, senior vice president, infectious disease at AstraZeneca, said: “Omniose’s bioconjugation platform represents a differentiated approach to engineering conjugate vaccines and strengthens our ability to develop novel vaccines against serious bacterial infections. Building on the strong scientific collaboration between our teams, we look forward to advancing these programs and realizing the potential of this technology for patients.”¹

What did AstraZeneca acquire in the Omniose deal?

Omniose is an early-stage company developing polysaccharide conjugate vaccines against serious bacterial threats.¹ The transaction adds its proprietary bioconjugation platform and related expertise to AstraZeneca’s preclinical vaccine programs.¹

The announcement did not disclose financial terms, target pathogens or development timelines.

What did the earlier AstraZeneca–Omniose collaboration cover?

The companies signed the exclusive agreement in January 2024, giving AstraZeneca rights to the platform for up to three years to research vaccines against bacterial pathogens in its early vaccines and immune therapies pipeline.² At the time, Omniose said earlier bioconjugation enzymes could address only a limited range of bacterial targets and that its approach expands that scope.²

That assessment comes from the company, and the acquisition announcement includes no supporting data. Christian Harding, chief scientific officer and co-founder of Omniose, said: “This milestone reflects the work of exceptional and complementary teams. AstraZeneca has been a trusted partner for several years, and this acquisition gives our platform the best chance to reach the patients it was built to serve.”¹

How does bioconjugation differ from chemical conjugation?

Antibiotic-resistant bacterial infections are a growing public health threat, and glycoconjugate vaccines are among the most effective tools against bacterial disease, according to a 2019 review.³ These vaccines link a bacterial polysaccharide to a carrier protein, a pairing that supports durable immune memory.

Licensed products have historically covered a narrow set of pathogens, including Haemophilus influenzae type b, Neisseria meningitidis and some Streptococcus pneumoniae strains.³ Conventional manufacture requires purifying the polysaccharide from the pathogen, purifying and activating the carrier protein, chemically joining the two and purifying the product again.

Reviewers describe this multistep process as costly and prone to batch-to-batch variation.³ Omniose’s approach instead has a single E. coli cell produce the polysaccharide antigen, an engineered carrier protein and a conjugating enzyme that links them.¹

Researchers in the field describe bioconjugation as a lower-cost, more flexible alternative to chemical conjugation, and several bioconjugate vaccines are in clinical trials.⁴

What remains unresolved after the acquisition?

The programs involved are preclinical, so the announcement offers no clinical safety or immunogenicity data for candidates built on the platform. It also provides no yield, purity, or cost figures that would show whether in-cell conjugation delivers the manufacturing advantages attributed to the approach.

Omniose has said its platform can attach virtually any bacterial polysaccharide antigen to engineered carrier proteins, a claim the announcement does not support with published data.¹ Technical constraints in the field are documented.

The 2019 review noted that the coupling enzyme most widely used in bioconjugation is incompatible with most pneumococcal capsular serotypes, and that expressing diverse polysaccharides in E. coli can place a metabolic burden on the host cell, though newer enzymes have broadened the range of glycans that can be transferred.³ A 2025 review describes the technology’s promise of low-cost, custom-designed vaccines alongside its continued development.⁴

Next steps will depend on disclosures AstraZeneca has not yet made: which pathogens the programs will prioritize, when candidates might approach clinical testing and whether the single-cell process holds up at manufacturing scale.

Sources

1. Omniose announces its acquisition by AstraZeneca. News release. Business Wire. November 10, 2026. Accessed November 10, 2026. https://www.businesswire.com/news/home/20261110984674/en/Omniose-Announces-Its-Acquisition-by-AstraZeneca

2. Omniose announces scientific collaboration with AstraZeneca to research vaccines for serious bacterial diseases. News release. Business Wire. January 5, 2024. Accessed November 10, 2026. https://www.businesswire.com/news/home/20240105555701/en/Omniose-Announces-Scientific-Collaboration-With-AstraZeneca-to-Research-Vaccines-for-Serious-Bacterial-Diseases

3. Kay E, Cuccui J, Wren BW. Recent advances in the production of recombinant glycoconjugate vaccines. npj Vaccines. 2019;4:16. doi:10.1038/s41541-019-0110-z

4. Wren BW, Hall CL, Terra VS, et al. Recent advances in bioconjugate vaccine development. Vaccines (Basel). 2025;13(7):703. doi:10.3390/vaccines13070703